GENFIT - ALGFT - FR0004163111

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40
Gebruikersavatar
Naz-T
Forum actieveling
Forum actieveling
Berichten: 950
Lid geworden op: 06 sep 2018 20:48
waarderingen: 405
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Naz-T »

TO van 4,01? Nieuws?



Bullseye65
Forum gebruiker
Forum gebruiker
Berichten: 106
Lid geworden op: 15 mar 2019 12:09
waarderingen: 22
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Bullseye65 »

Naz-T schreef:
02 mar 2020 08:18
TO van 4,01? Nieuws?
ben er altijdje terug uit. Vandaag paar ritjes doen....
Quantum Genomics,,Acacia, Vivoryon, biophytis

Bullseye65
Forum gebruiker
Forum gebruiker
Berichten: 106
Lid geworden op: 15 mar 2019 12:09
waarderingen: 22
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Bullseye65 »

Gefit getankt in de solden...12.75 ( te laat opgemerkt, kon beter)
Quantum Genomics,,Acacia, Vivoryon, biophytis

Soppi
Forum actieveling
Forum actieveling
Berichten: 472
Lid geworden op: 20 dec 2012 09:04
waarderingen: 438
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Soppi »

We blijven met vertrouwen en vol ongeduld uitkijken naar de nakende resultaten van de de phase 3 van Elafibranor
Bij positieve resultaten.... is the sky the limit!!!


https://seekingalpha.com/article/433379 ... approaches

Genfit: Near-Term Upside Of 650% As Read-Out Of The Year Approaches
Mar. 24, 2020 12:45 AMGenfit SA (GNFT)ABBV, AGN, BMY
Summary
NASH is a common disease with an expected market size of 20 Bn. $ in 2030 and currently no approved drugs.
A handful of companies including most of big pharma are in the NASH race to become early market entrants.
Crucial phase III read-out of Genfit's lead candidate in NASH (Elafibranor) expected in a matter of weeks.
If proven effective Elafibranor will become the first drug on the market against NASH resolution and the first suitable backbone therapy.
Near-term upside of 650% can be unlocked by a big pharma acquisition. Potential acquirers are identified below.
Stofke liked last!

Stofke
Premiummember
Premiummember
Berichten: 901
Lid geworden op: 13 okt 2017 16:18
waarderingen: 531
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Stofke »

GENFIT: Update on Regulatory and Clinical Activities Amid the COVID-19 Pandemic

https://ir.genfit.com/news-releases/new ... d-covid-19

Stofke
Premiummember
Premiummember
Berichten: 901
Lid geworden op: 13 okt 2017 16:18
waarderingen: 531
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Stofke »

GENFIT S A/ADR (NASDAQ:GNFT) Receives Buy Rating from B. Riley

https://www.dailypolitical.com/2020/04/ ... riley.html

Stofke
Premiummember
Premiummember
Berichten: 901
Lid geworden op: 13 okt 2017 16:18
waarderingen: 531
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Stofke »

COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout

Genfit has told investors that it does not expect the COVID-19 pandemic to “significantly delay” the unblinding of its phase 3 nonalcoholic steatohepatitis (NASH) data. The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.

France’s Genfit disclosed the need to wait on FDA feedback before taking a look at the phase 3 data last month, triggering a drop in its stock price. At that time, Genfit said it was delaying the unblinding “to incorporate the latest FDA insights expected by the end of March.” With March now almost over, Genfit has provided an update on the situation.

In the latest update, Genfit said that it does not “currently anticipate that the COVID-19 situation will significantly delay receipt of this feedback.” FierceBiotech is awaiting clarification from Genfit, but the comment, and timing of its release, suggests the feedback will be later than originally expected.

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.
How much later has implications for Genfit’s efforts to bring elafibranor to market in NASH. Genfit thinks the results from the 1,000 or so patients in the locked database will support FDA approval, but that will remain uncertain until the feedback is shared and the data are unblinded and analyzed.

Intercept Pharmaceuticals, the one company Genfit is trailing in the NASH race, has also faced some COVID-19 disruption, with the FDA delaying an advisory committee meeting to discuss its filing from April to June. Intercept has a PDUFA action date of June 26.

While Genfit thinks COVID-19 is unlikely to significantly set back the unblinding of its data, other parts of its operation face more disruption. Genfit has paused all phase 1 trials of elafibranor. The studies “are necessary to support the elafibranor NDA submission for NASH,” Genfit said. Genfit has also paused enrollment in a phase 2 liver fat study and put the initiation of a phase 2 NASH combination trial and a phase 3 primary biliary cholangitis (PBC) program on hold.

In the face of the disruption, Genfit is trying to ensure its studies can hit the ground running when the pandemic subsides. Work toward the phase 2 combination trial and phase 3 PBC study is ongoing, and “all supporting activities pertaining to continuation of ongoing studies or the initiation of new studies will continue.”

Bron: FierceBiotech

Stofke
Premiummember
Premiummember
Berichten: 901
Lid geworden op: 13 okt 2017 16:18
waarderingen: 531
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Stofke »

GENFIT Reports Full-Year 2019 Financial Results and Corporate Update

https://ir.genfit.com/news-releases/new ... -corporate
Frakke liked last!

Stofke
Premiummember
Premiummember
Berichten: 901
Lid geworden op: 13 okt 2017 16:18
waarderingen: 531
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Stofke »

HC Wainwright reduced their target price on shares of GENFIT from $58.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, April 9th.

Stofke
Premiummember
Premiummember
Berichten: 901
Lid geworden op: 13 okt 2017 16:18
waarderingen: 531
Contacteer:

Re: GENFIT - ALGFT - FR0004163111

Bericht door Stofke »

Why Genfit (GNFT) Stock Might be a Great Pick

https://finance.yahoo.com/news/why-genf ... soc_trk=tw

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen.


Plaats reactie